Evidence map›Paper›PMID 30136405›Full record

ArticleCNS neuroscience & therapeutics2019

DPP-4 inhibitors promote proliferation and migration of rat brain microvascular endothelial cells under hypoxic/high-glucose conditions, potentially through the SIRT1/HIF-1/VEGF pathway.

Dong-Hua Mi, Hong-Juan Fang, Guang-Hui Zheng, Xian-Hong Liang, Ya-Rong Ding, Xin Liu, Li-Ping Liu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Neurovascular Actions of Dipeptidyl Peptidase-4 Inhibitors and Their Implications for Cognitive Dysfunction in Type 2 Diabetes Mellitus.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dong-Hua MiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-8845-8769
Hong-Juan FangDepartment of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Guang-Hui ZhengDepartment of Clinical laboratory, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xian-Hong LiangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ya-Rong DingDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xin LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Li-Ping LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVascular disease in diabetes, for example, stroke, presents a significant public health burden. Recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin has been found to counteract stroke among diabetic patients, showing great promise in drug repurposing and indication expansion. However, the molecular basis of this protection mechanism remains unknown.

methodsThe expression and localization of DPP-4 in rat brain microvascular endothelial cells (rBMVECs) were assessed with immunofluorescent staining and Western blotting. The effects of DPP-4 inhibitors on cell proliferation and migration of rBMVECs were determined using MTT and transwell assays, separately. The influence of DPP-4 inhibition on the expression of molecular markers (eg, VEGF, eNOS, HIF-1α. SIRT1) was examined at both mRNA and protein levels with qRT-PCR and Western blotting, individually.

resultsDPP-4 inhibitors (40 nmol/L linagliptin, 30 μmol/L berberine) offer protection from hypoxia/high glucose induced impairments in the proliferation and migration of rBMVECs. Treatment with DPP-4 inhibitors counteracted the attenuating effects of hypoxic/high-glucose conditions on the expression of VEGF, eNOS, HIF-1α, and SIRT1, which can be completely eliminated by the inhibition of SIRT1 with 1 mmol/L nicotinamide.

conclusionsThe protection of rBMVECs from hypoxia/high-glucose induced impairment by DPP-4 inhibitors may be mediated by the SIRT1/HIF-1α/VEGF pathway.

Indexed as

AnimalsBrainCell HypoxiaCell LineCell MovementCell ProliferationDipeptidyl-Peptidase IV InhibitorsEndothelial CellsGlucoseHypoxia-Inducible Factor 1, alpha SubunitMicrovesselsNeuroprotective AgentsNitric Oxide Synthase Type IIIRatsSignal TransductionSirtuin 1Dipeptidyl-Peptidase IV InhibitorsGlucoseHif1a protein, ratHypoxia-Inducible Factor 1, alpha SubunitNeuroprotective AgentsNitric Oxide Synthase Type IIINos3 protein, ratSirt1 protein, ratSirtuin 1Vascular Endothelial Growth Factor Avascular endothelial growth factor A, ratdiabetesDPP-4 inhibitorendothelial dysfunctionSIRT1stroke

Identifiers

PMID30136405
PMCPMC6488877
OpenAlexW2888641023

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.